JERSEY CITY, N.J. — November 17, 2025 — Leads & Copy — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company, announced that its triterpenoid antifungal platform will be among the projects funded by a federal grant awarded to a new accelerator consortium.
The five-year federal grant will establish a Center of Excellence in Translational Research (CETR) between researchers from the Bloomberg School and the CDI, along with academic and commercial collaborators. The CETR is expected to receive about $7 million annually, with support from the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID).
The novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform will be among the five projects funded. Researchers from Hackensack Meridian Center for Discovery and Innovation (CDI) and the Johns Hopkins Bloomberg School of Public Health will lead the consortium.
David Angulo, M.D., President and Chief Executive Officer of SCYNEXIS, said the new grant from the NIH provides essential funding to support the development of new therapeutics that can address the growing threat from resistant fungal infections. Approximately four million annual deaths are attributable to fungal infections globally.
Angulo said that a series of next-generation fungerp candidates are included in this research collaboration, with the aim to progress their development from early preclinical stage to IND ready candidates. The company has selected a few fungerps with attributes including activity against resistant fungi and differentiated pharmacological properties.
Triterpenoid antifungals (fungerps) are structurally distinct glucan synthase inhibitors being developed to address the threat posed by antimicrobial resistance (AMR) in systemic fungal diseases. The triterpenoid class of antifungals represents the first new class of antifungal compounds approved since 2001. These agents combine the activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
Ibrexafungerp, the first representative of this novel class, has been licensed to GSK. The U.S. Food and Drug Administration (FDA) approved BREXAFEMME® (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC) in 2021 and for reduction in the incidence of recurrent VVC in 2022.
SCY-247 is a second-generation fungerp, in Phase 1 of development and has demonstrated in vitro and in vivo broad-spectrum antifungal activity, including against multidrug resistant fungal pathogens. Additional antifungal assets from this novel class are currently in pre-clinical and discovery phases of development.
The Center for Discovery and Innovation (CDI) translates current innovations in science to improve clinical outcomes for patients. More than 34 laboratories, 200+ professional researchers and physician-scientists at the CDI are focusing on cancer, infectious diseases, autoimmune disorders, and other acute and chronic diseases.
The CDI harnesses advances in genetics, molecular biology, clinical immunology, imaging, and behavioral sciences to better diagnose, treat and prevent disease through personalized medicine approaches. For additional information, please visit www.hmh-cdi.org.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing medicines to help patients overcome difficult-to-treat infections that are becoming increasingly drug-resistant. SCYNEXIS is developing the company’s proprietary antifungal platform “fungerps.”
Irina Koffler
LifeSci Advisors
Tel: 917-734-7387
ikoffler@lifesciadvisors.com
Source: SCYNEXIS
